Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine
1. A next-generation live-attenuated yellow fever vaccine (vYF) demonstrated noninferior immunogenicity in contrast to the standard vaccine, with practically common seroconversion by one month after vaccination. 2. Safety profiles have been related between teams, with no vaccine-related severe hostile occasions noticed over one yr of follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Yellow fever…
